• Skip to main content
  • Skip to secondary menu
  • Skip to footer
Clinical Digital Resource Collaborative

Clinical Digital Resource Collaborative

Designed and developed in the North East and North Cumbria by local GPs

National Health Service
  • Home
  • About Us
  • The Team
  • Resources
    • Referral Forms
    • EMIS Resources
      • CDRC EMIS Access
      • Long Term Condition (LTC) Management
      • Impact and Investment Fund (IIF)
      • Medicine Management
        • Precision Monitoring
        • DMARDs and High Risk Drugs
        • Safe Prescribing of Opioids / Opiates
      • Specialties
        • Cancer Guide for EMIS
        • EMIS Cardiovascular Overview
          • Atrial Fibrillation Guide for EMIS
          • CDRC Precision CVD Prevention Template
          • Lipids, Familial Hypercholesterolaemia (FH), PCSK9i & Inclisiran Guide for EMIS
          • Peripheral Arterial Disease EMIS Guide
        • Infection
          • Infections Guide for EMIS
          • Blood Borne Virus (BBV)
        • Neurology Guide for EMIS
        • Respiratory Overview
          • BeatAsthma+
    • SystmOne Resources
      • National Early Warning Score 2 (NEWS2) Guide for SystmOne
      • Getting Started
        • Getting Started – Access
        • Getting Started – How-To’s
      • SystmOne Administration
      • Contract Management
        • Impact and Investment Fund (IIF)
        • Vaccinations
      • Long Term Condition Management
        • Call/ Recall System
        • Recall Recovery System
        • Care Planning
      • Safeguarding System
        • Safeguarding Adults
        • Safeguarding At Risk of Harming Others
        • Safeguarding Family/Household Cause for Concern
        • Safeguarding Children
      • Medicine Management
        • Drugs Requiring Monitoring System
        • Safety & Reviews
        • Safe Prescribing of Opioids / Opiates
        • Safe Prescribing of NSAIDS
        • Safe Prescribing of Lithium
        • Safe Prescribing of Valproate
        • Safe Prescribing of Corticosteroids / Steroids
      • Specialties
        • Blood Borne Virus (BBV) Test Alert for SystmOne
        • BeatAsthma+ Guide for SystmOne
        • Cancer Overview
          • Cancer
          • Suspected Cancer
        • Cardiovascular Overview
          • Cardiology Results
          • Hypertension & Blood Pressure
          • Atrial Fibrillation (AF)
          • Integrated CVD Prevention
          • Peripheral Arterial Disease (PAD)
        • SystmOne Diabetes Overview
          • SystmOne Diabetes Management
          • SystmOne Diabetes Prevention
          • SystmOne Diabetic Kidney Disease
        • ENT Infections
        • Geriatrics Overview
          • Care for Frail Patients
          • Comprehensive Geriatric Assessment
          • Co-ordinated Care
        • Haematology
        • Infection Overview
        • Learning Disabilities
        • Lifestyle
        • Lipids, Familial Hypercholesterolaemia, PCSK9i & Inclisiran Overview
          • Lipids, Familial Hypercholesterolaemia (FH), PCSK9i & Inclisiran Search Guide for SystmOne
          • Lipids Protocols
          • Lipids Opt-In Resources
          • Lipid Details and Lipid Lowering Templates
          • Lipid Lowering Template
          • Lipid QoF Support
          • Screening for Familial Hypercholesterolaemia
          • Aetiology of Abnormal Lipids
          • Lipids Strategy
          • Lipids – Recommended Batch Searches
        • MSK Referral Management
        • Neurology
        • Obesity Resources
        • Ophthalmology
        • Palliative Care
        • SystmOne Renal/Urology Overview
          • Chronic Kidney Disease (CKD)
        • Respiratory Overview
          • Asthma Resources
          • Respiratory Infections
        • Rheumatology Overview
          • Bone Health
      • Women’s Health Overview
        • Gynaecology Resource Overview
          • Cervical Screening
          • Contraception
          • Prolapse
      • Vaccination Overview
        • COVID-19 Resources- SystmOne
        • Influenza Vaccination
        • Meningitis B Vaccination
        • Meningitis ACWY Vaccination
        • Pneumococcal Vaccination
        • Shingles Vaccination
  • FAQs
  • News and Events
    • Demonstrations
    • Events
      • Recordings
    • Articles
    • Conference abstracts
  • Contact us
You are here: Home / Resources / SystmOne Resource Centre / SystmOne Specialties / Lipids, Familial Hypercholesterolaemia, PCSK9i & Inclisiran Overview / Screening for Familial Hypercholesterolaemia

Screening for Familial Hypercholesterolaemia

Patients who may have Familial Hypercholesterolmaemia (FH) can be identified in the following searches in the CDRC Quality > Lipids 

Search NameSearch Returns Action 
? 2.0 Case Finding – Consider screening for familial hypercholesterolamia Patients who have a significant chance of familial hypercholesterolaemia Screen for FH – see below 
? 2.01 Case Finding – Consider screening for familial hypercholesterolamia (also eligible for IFF FH referral)Patients in 2.0 who are also appear in the IIF CVD04 ‘consider for FH assessment’ denominator Screen for FH – see below 
? 2.02 Case Finding – Consider screening for familial hypercholesterolamia – highest risk patientsPatients in 2.0 who are at highest risk of FH – for areas with limited resources – concentrate on these patients Screen for FH – see below 
? 2.1 Case Finding – Eligible for IFF FH referral but FH less likelyPatients who appear in the IIF CVD04 ‘consider for FH assessment’ denominator, who are less likely to have FH Screen for FH – see below, but likely to have a secondary cause of hyperlipidaemia 
? 2.2 Case Finding –  Code for FH but not genetic code – consider need for genetic testingPatients with a code suggesting FH e.g. Possible FH who don’t have a definitive FH code Review record and consider: Adding definitive code if appropriate Referral for genetic testing Removal of code if incorrect – e.g. secondary hyperlipidaemia 

Patients are identified using a combination of tools – NICE guidance, estimated Dutch Lipid Clinic Network scores and estimated Welsh FH Score with adjustment for high triglyceride levels. 

Two pages of the Lipids Details Template will help with screening 

  • Aetiology page – page showing information about possible causes of hyperlipidaemia, especially, secondary causes – Aetiology of Abnormal Lipids 
  • FH Screening page – calculate the Dutch Lipid Clinic Network Score.  Local referrals protocols vary, but patients with a DLCNS >=6 are usually referred to a lipid clinic to consider FH genetic testing. 

The central panel shows relevant information from the record and the buttons on the left allow this information to be expanded. 

Record the following if not already recorded: 

  • Family history of CVD and/or hyperlipidaemia 
  • Family history of tendinous xanthomata 
  • History of tendinous xanthomata 
  • History of arcus 

Then use this information to calculate a Dutch Lipid Clinic Network Score. 

Consider secondary causes of hyperlipidaemia such as uncontrolled diabetes mellitus, untreated hypothyroidism, chronic renal failure, nephrotic syndrome, cholestasis, hypopituitarism, anorexia, obesity, anticonvulsants, antipsychotics, steroids, cyclosporin, anti-retrovirals, retinoids.  Some of these issues will be shown in the panel towards the bottom of the template.  

Use the bottom boxes to record referral to or consultation in lipid clinics (recent or historic) 

Calculating the highest LDL-cholesterol 

It can be difficult to find a pre-treatment LDL-cholesterol in some patients who have been on lipid lowering therapy for many years.  The Lipids Results button will show all previous lipid results to help with this. 

The LDL-C can be estimated using Friedewald equation: 

  • LDL-C = non-HDL-C minus (triglycerides / 2.2).   
  • This formula is not valid if the triglyceride level is >=4.5.  In addition the DLCNS is not valid if the lipid values are associated with a triglyceride level >2.3.   

In the example below the pre-treatment non-HDL can be estimated by subtracting the HDL (estimated at around 1, looking at subsequent values) from the total cholesterol, e.g. 8.2-1 = 7.2  

Then estimating that the pre-treatment triglyceride level was around 3, LDLC= 7.2-3/2.2 = ~5.8 

Graph 
Data Settings Graph 
Preset All Lipid Tests (BC) 
Z] Only show readings that the patient has at least one of 
Edt Presets 
Date 
25 dui 2003 
30 Dec 2003 
01 Mar 2004 
01 Mar 2004 
01 Mar 2004 
20 May 2004 
02 Aug 2004 
08 Nov 2004 
08 Nov 2004 
07 Mar 2005 
06 Dec 2005 
28 Feb 2006 
04 Dec 2006 
21 Mar 2007 
02 Nov 2007 
08 Dec 2008 
16 Nov 200g 
20 Jan 2010 
lgMay 2010 
IODec 2010 
21 Dec 2011 
13 Dec 2012 
dan 2014 
14 Jan 2015 
11 Dec 2015 
02 Dec 2016 
30 Nov 2017 
Serum LDL choL„ Serum choleste 
Serum HDL chu 
06 
1 43 
Serum choleste 
Serum triglyceride levels 
401 
1 32 
221 
236

This patient’s lipid profile is highly suggestive of metabolic syndrome rather than FH, with low HDL-C, raised TGs and a BMI of >35.   

Footer

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter
  • Terms of Reference
  • Ethics & Governance
  • Privacy policy
  • Terms of use
  • Join CDRC Precision

Copyright © 2023 Clinical Digital Resource Collaborative